The XF series of compounds from Destiny Pharma represents a revolutionary approach to the prevention and treatment of infection – particularly infections caused by multidrug-resistant pathogens.

In order to ensure the highest quality of its research, Destiny works with, and is advised by, leading experts in microbiology, infection control and infectious disease. Given the unique mechanism of action, XF drugs (and two next-generation drug series, see below) show promise in many indications and Destiny is actively pursuing the following:

Topical use

Infection is common in serious burns and Destiny is researching the use of XF compounds in preventing infection and thus aiding the healing process. Skin ulcers are common, particularly in the elderly. The breakdown of local tissue, together with a less robust immune system, means that infection of skin ulcers is common. Destiny is researching the application of its XF products to prevent infection of ulcers and promote wound healing.

Oral use

Gut-borne pathogens such as Clostridium difficile now represent a significant health challenge, especially in healthcare facilities. The potential use of XF drugs in decolonising the gastrointestinal tract is under investigation.

Systemic use

Serious infections caused by multidrug-resistant bacteria are not restricted to the skin. Destiny is researching the systemic application of its products in the treatment of such infections. In order to ensure the highest quality of its research, Destiny works with leading experts in infection control and infectious disease.

Pipeline – Next-generation antimicrobials

Destiny is continuing its research into novel antimicrobial products and has already synthesised two further drug series, codenamed DPD and MQ, which are based on the fundamental breakthrough nature of the XF drugs. These are designed to enhance the range of clinical applications for Destiny’s products.